Is ABT or AEMD more undervalued in 2026?

CirclFi compares Abbott Laboratories (ABT) and Aethlon Medical, Inc. (AEMD) using 13 institutional-grade valuation models. ABT has a Quality of Company score of 9.9/10 while AEMD scores 4.6/10.

Which is a better buy — ABT or AEMD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ABT and AEMD valuations compare?

ABT at $85.60 and AEMD at $2.21 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ABT vs AEMD Valuation Comparison 2026 — Intrinsic Value Analysis

ABT

Medical Devices

Abbott Laboratories

Quality

9.9

out of 10

Value Trap

—

Price

$85.60

Last close

Models

13/13

Active

AEMD

Medical Devices

Aethlon Medical, Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$2.21

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	ABT Fair Value	ABT Upside	AEMD Fair Value	AEMD Upside
Bayesian DCF	Intrinsic	$63.50	-25.8%	$2.86	+29.3%
Earnings Power Value	Intrinsic	$8.66	-89.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$46.04	-46.2%	$0.40	-82.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ABT vs AEMD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ABT vs AEMD — Which Stock Is More Undervalued?

ABT scores higher with a 9.9/10 quality rating vs AEMD's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Abbott Laboratories (ABT) and Aethlon Medical, Inc. (AEMD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ABT currently trades at $85.60 with a QOC of 9.9/10, while AEMD trades at $2.21 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).